Directmeds Announces Expanded Access To Doctor-Guided GLP-1 Weight Management Programs Starting At $249 Per Month

(MENAFN- GlobeNewsWire - Nasdaq) New York, NY, Aug. 28, 2026 (GLOBE NEWSWIRE) --

Telehealth platform expands access to physician-guided GLP-1 treatment with transparent pricing, nationwide virtual care, and ongoing clinical support.

DirectMeds today announced the continued expansion of its telehealth platform, providing eligible adults across the United States with convenient access to doctor-guided GLP-1 weight management programs starting at $249 per month. The company is expanding access to personalized virtual healthcare by combining licensed medical oversight, prescription management, and ongoing patient support into one streamlined telehealth experience.

As demand for virtual healthcare continues to grow, DirectMeds aims to simplify the patient journey by allowing individuals to complete consultations, receive provider evaluations, and manage treatment entirely online. The platform connects patients with licensed U.S. healthcare providers who determine eligibility based on individual medical history and treatment goals before prescribing medication when clinically appropriate.

Once approved, prescriptions are fulfilled through licensed U.S. pharmacies and shipped directly to patients using temperature-controlled packaging with shipment tracking. The company states that provider reviews are typically completed within a few business hours, allowing qualified patients to begin treatment quickly while remaining under ongoing medical supervision.

DirectMeds currently offers multiple GLP-1 treatment options, including sublingual semaglutide and injectable semaglutide or tirzepatide, giving healthcare providers flexibility to recommend personalized treatment plans based on each patient's clinical needs and lifestyle preferences. Patients continue receiving support from licensed providers and nursing professionals throughout their treatment journey, with follow-up care and dosage adjustments managed through the company's secure online platform.

"Our goal is to make medically supervised weight management more accessible, affordable, and transparent," said a DirectMeds spokesperson. "By combining licensed healthcare providers, virtual consultations, ongoing clinical support, and predictable pricing into one comprehensive program, we are helping patients access quality care through a convenient digital healthcare experience."

Transparent Pricing Designed for Simplicity

As part of today's announcement, DirectMeds confirmed that its pricing model is designed to provide patients with a single, transparent monthly cost that includes provider oversight, prescribed medication when approved, ongoing clinical support, and shipping.

Treatment Plan	Monthly Price
Sublingual Semaglutide	Starting at $249/month
Injectable (Semaglutide or Tirzepatide)	Starting at $297/month

According to the company, there are no separate membership fees or hidden charges, allowing patients to better understand the total cost of treatment before enrolling.

Individuals interested in determining whether they may qualify for treatment can complete the company's complimentary online assessment at:

Take the Free Assessment:

Key Features of the DirectMeds Platform

• Doctor-guided treatment plans from licensed U.S. healthcare providers
• Programs starting at $249 per month
• No separate membership fees
• Provider consultation, medication, clinical support, and shipping included in one monthly price
• Ongoing access to licensed nursing staff and healthcare providers
• Fast prescription review and medication fulfillment
• Nationwide telehealth access
• HSA and FSA eligible payment options
• Secure virtual patient portal for ongoing care

Beyond weight management, DirectMeds also offers virtual healthcare services for hormone health, sexual health, skin care, hair restoration, wellness, and other patient-focused treatment programs. The company says its broader telehealth platform enables patients to access multiple healthcare services through one secure digital experience.

DirectMeds emphasizes that every treatment recommendation begins with an individual medical evaluation conducted by a licensed healthcare provider. GLP-1 medications are prescribed only when medically appropriate, and not every patient will qualify for treatment. Clinical decisions are based on each patient's health history, current medications, and overall medical profile.

The company believes continued innovation in virtual healthcare can improve access to evidence-based weight management solutions while reducing barriers associated with traditional in-person care. By combining physician oversight with digital convenience and transparent pricing, DirectMeds aims to deliver a patient-centered healthcare experience for adults seeking medically supervised treatment.

Individuals interested in learning more about DirectMeds or determining their eligibility are encouraged to complete the company's free online assessment and consult with a licensed healthcare provider regarding available treatment options.

About DirectMeds

DirectMeds is a U.S.-based telehealth platform connecting patients with licensed healthcare providers for medically supervised treatment programs. Through virtual consultations, personalized care plans, ongoing provider support, and prescription fulfillment through licensed U.S. pharmacies, the company delivers accessible healthcare solutions focused on transparency, convenience, and patient-centered care.

Media Contact

DirectMeds Media Relations

Email: ...

Website:

Disclaimer

GLP-1 medications are available only after evaluation and approval by a licensed healthcare provider. Individual results may vary. This press release is provided for informational purposes only and should not be considered medical advice.

Information contained on this page is published by SP Tech Solutions and content provided by authorized third party content provider. SP Tech Solutions and this Site make no warranties or representations in connection therewith.

CONTACT: DirectMeds Media Relations Email:... Website:

MENAFN28082026004107003653ID1111592095